Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.

Stopped Study was terminated due to strategic considerations and not due to safety.

Conditions

• Gastrointestinal Tumors
• Colorectal Adenocarcinomas
• Gastric Adenocarcinomas
• Esophageal Adenocarcinomas

Interventions

• DRUG: PF-07062119
• DRUG: Anti-PD1
• DRUG: Anti-VEGF

Sponsor

Pfizer